Results 151 to 160 of about 92,879 (318)

Determination of OPC-17116, a new fluoroquinolone, in human alveolar macrophages and other biological matrices by high performance liquid chromatography (HPLC) [PDF]

, 1994
J Woodcock, Jennifer M. Andrews, D. Honeybourne, Richard Wise   +3 more
openalex   +1 more source

Fighting Antibiotic Resistance: Insights Into Human Barriers and New Opportunities

BioEssays, Volume 47, Issue 6, June 2025.
Antibiotic resistance is a public health issue leading to the emergence of multi‐resistant bacteria. Human‐dependent factors are now driving the increase of resistance, notably through antibiotic misuse in human and animal health and environmental pollution.
Aubin Pitiot, Camille Rolin, Carole Seguin‐Devaux, Jacques Zimmer   +3 more
wiley   +1 more source

Les souches de P. aeruginosa (pa) resistant a la pefloxacine (p) devraient-elles etre testees vis-a-vis des autres fluoroquinolones ?

, 1989
C. Chidiac, M. Roussel‐Delvallez, G. Beaucaire, J. Rogier, Éric Senneville, B Sivery, O. Leroy, C. Beuscart, Y Mouton, G. Martin, A Fourrier   +10 more
openalex   +1 more source

The New Fluoroquinolones: A Critical Review [PDF]

, 1999
George G. Zhanel, Andrew Walkty, Lavern M. Vercaigne, James A. Karlowsky, John M. Embil, Alfred S. Gin, Daryl J. Hoban   +6 more
openalex   +1 more source

Impact of Regulatory Post‐Market Safety Advisories on Prescribing Practices: An Interrupted Time Series Analysis

Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1754-1762, June 2025.
Less frequent adverse drug reactions are usually discovered after a drug's release to the market, making effective and timely communication of regulatory post‐market advisories essential for preventing emerging adverse effects. Time series analysis is a key study design for assessing the impact of post‐market safety advisories.
Seonji Kim, Subin Kim, Chungsoo Kim, Junhyuk Chang, Rae Woong Park, Kyung Won Kim, Seng Chan You   +6 more
wiley   +1 more source

Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628 [PDF]

, 1995
A L Barry, Peter Fuchs, S D Allen, Fred C. Tenover, J H Jorgensen, L. Barth Reller   +5 more
openalex   +1 more source

Drug‐Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources

Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1811-1819, June 2025.
Adverse drug reactions (ADRs) are a common cause of morbidity and mortality in hospitalized patients. Identification of ADRs in clinical practice, surveillance and research is essential to prevent further harm. The aim of this study was to assess the likelihood of drugs contributing to clinically important inpatient adverse events, in order to provide ...
Anna Maria Wermund, Annette Haerdtlein, Wolfgang Fehrmann, Clara Weglage, Tobias Dreischulte, Ulrich Jaehde   +5 more
wiley   +1 more source

Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates

, 1992
Katsumasa Sato, Kazuki Hoshino, M Tanaka, I Hayakawa, Y Osada   +4 more
openalex   +1 more source

Examination of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Mutants with Low-Level Fluoroquinolone Resistance [PDF]

, 1998
Mark C. Sulavik, Neil L. Barg
openalex   +1 more source

Functionalized Polydopamine Nanoparticles: A Promising Drug Delivery Platform for the Treatment of Tuberculosis

Drug Development Research, Volume 86, Issue 4, June 2025.
ABSTRACT Tuberculosis (TB) is considered a major infectious disease by the World Health Organization. The WHO estimates that there are 1.8 million TB deaths, and 10.4 million new cases of the disease reported yearly. While there are conventional therapies for TB, they have drawbacks such as a lengthy pill regimen, rigorous scheduling, and protracted ...
Nnamdi Ikemefuna Okafor, Precious Nnaji, Ngozi Francisca Nnolum‐Orji, Yahya E. Choonara   +3 more
wiley   +1 more source